Treatment approach for newly diagnosed TP53-mutated AML.

# Many clinicians prefer less intensive regimens to reduce toxicity, even in patients who are eligible, given the poor outcomes associated with intensive chemotherapy. Robust data supporting this practice are lacking.

* Adding venetoclax to the treatment regimen may improve the likelihood of response, but mounting data suggest that this is unlikely to improve survival.

^ Even though allo-HSCT is the only potentially curative therapy, posttransplant outcomes remain poor. Consequently, the risk/benefit assessment ends up not favoring allo-HSCT for many patients.

Created with BioRender.com.